EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of FGF-mediated conditions by administration of a cardiac glycoside or aglycone derivative thereof



Treatment of FGF-mediated conditions by administration of a cardiac glycoside or aglycone derivative thereof



Official Gazette of the United States Patent & Trademark Office Patents 1235(1), June 6



This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1alpha, IL-1beta and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.

(PDF 0-2 workdays service: $29.90)

Accession: 035980408

Download citation: RISBibTeXText



Related references

Reliability of cardiac glycoside administration under ambulatory conditions. Das Deutsche Gesundheitswesen 27(23): 1099-1104, 1972

Affinoside b a cardiac glycoside with a diosphenol system in the aglycone from anodendron affine. Chemical & Pharmaceutical Bulletin (Tokyo) 27(10): 2463-2467, 1979

Influence of calcium concentration on the rate of onset of cardiac glycoside and aglycone inotropism. Journal of Pharmacology and Experimental Therapeutics 198(3): 680-686, 1976

Digitanol glycoside XII Composition of kondurangogenin A, the aglycone of an ester glycoside of Marsdenia cundurango bark. Tetrahedron: 1777-1795, 1965

The biosynthesis of the cardenolid- and spirostan glycoside in Digitalis lanata EHRH. Comparison of formation rates. Glycoside and aglycone, 274. Helvetica Chimica Acta 49(5): 1468-1474, 1966

Monoclonal antibody against cardiac glycoside and utilization thereof. Official Gazette of the United States Patent & Trademark Office Patents 1201(2): 1248-1249, Aug 12, 1997

Inotropic and toxic effects of a polar cardiac glycoside derivative in the dog. Circulation Research 43(6): 847-854, 1978

Pregnane glycoside of the epigenous parts of sarcostemma viminale d glycoside and aglycone 307 communication inst paper chromatography inst thin layer chromatography. Helvetica Chimica Acta 51(4): 738-766, 1968

Biochemical aspects of administration of hexa hydro ubi quinone 4 and derivative of reduced form thereof. Folkers, K And Y Yamamura (Ed ) Biomedical And Clinical Aspects Of Coenzyme Q Proceedings Of The International Symposium Lake Yamanaka, Japan, Sept 16-17, 1976 Xi+315p Illus Elsevier Scientific Publishing Co : Amsterdam, Netherlands; Elsevier/North-Holland, Inc : New York, N Y , Usa Isbn 0-444-41576-9 201-217, 1977

Cardiac glycoside and electrolytes in cardiac insufficiency part 2 influence of the cardiac glycoside on the cardiac contractility and the myo cardial electrolytes of the frogs heart. Kobe Journal of Medical Sciences 16(1): 11-26, 1970

Effects on sheep of the milkweeds Asclepias eriocarpa and A. labriformis and of cardiac glycoside-containing derivative material. Toxicon 17(2): 155-165, 1979

Effects on sheep of the milkweeds Asclepias eriocarpa and A. labriformis and of cardiac glycoside-containing derivative material. Toxicon 17(2): 155-165, 1978

Cardiac glycoside and electrolytes in cardiac insufficiency. II. Influence of the cardiac glycoside on the cardiac contractility and the myocardial electrolytes of the frog's heart. Kobe Journal of Medical Sciences 16(1): 11-26, 1970

Quercetin provides greater cardioprotective effect than its glycoside derivative rutin on isoproterenol-induced cardiac fibrosis in the rat. Canadian Journal of Physiology and Pharmacology 91(11): 951-959, 2014